UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________________ to _________________ Commission file number: 001-36724 The Joint Corp. (Exact name of registrant as specified in its charter) Delaware ...

The Joint Corp. (JYNT) came out with quarterly earnings of $0.04 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.05 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.06, delivering a surprise of -500%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.The Joint, which belongs to the Zacks Me ...

Financial Performance - Revenue for Q3 2024 increased by 2% to $30.2 million compared to $29.5 million in Q3 2023[3] - Net loss for Q3 2024 was $3.2 million, including a $3.8 million loss on disposition or impairment, compared to a net loss of $716,000 in Q3 2023[6] - Adjusted EBITDA for Q3 2024 was $2.4 million, down from $2.9 million in Q3 2023[6] - Total revenues for the three months ended September 30, 2024, were $30,198,490, compared to $29,473,949 for the same period in 2023, reflecting an increase of approximately 2.5%[28] - Net loss for the three months ended September 30, 2024, was $(3,165,139), compared to a loss of $(716,273) for the same period in 2023, indicating a significant increase in losses[28] - Net income for the nine months ended September 30, 2024, was a loss of $5,814,558 compared to a profit of $1,289,402 for the same period in 2023[29] - EBITDA for the nine months ended September 30, 2024, was a loss of $1,426,645, compared to $8,747,122 for the same period in 2023[30] - Adjusted EBITDA for the nine months ended September 30, 2024, was $8,065,873, slightly down from $8,165,066 in the same period of 2023[30] Sales and Growth - System-wide sales grew by 8% to $129.3 million, with system-wide comp sales reported at 4%[3] - The company expects system-wide sales for 2024 to be between $525 million and $535 million, adjusted from previous guidance[11] - System-wide comp sales for clinics open 13 months or more are projected to be between 3% and 4% for 2024[11] - New franchised clinic openings are expected to be between 55 and 60, adjusted from earlier estimates[11] Assets and Liabilities - Total current assets increased to $55,170,858 as of September 30, 2024, up from $44,335,538 as of December 31, 2023, representing a growth of approximately 24.5%[23] - Total liabilities decreased to $59,123,273 as of September 30, 2024, from $62,378,977 as of December 31, 2023, a reduction of about 5.4%[24] - Total assets decreased to $79,598,822 as of September 30, 2024, from $87,150,859 as of December 31, 2023, a decline of approximately 8.7%[25] - Goodwill decreased to $4,237,945 as of September 30, 2024, from $7,352,879 as of December 31, 2023, a reduction of about 42.5%[23] Cash Flow and Expenses - Unrestricted cash was $20.7 million at September 30, 2024, compared to $18.2 million at December 31, 2023[9] - Cash and cash equivalents rose to $20,737,769 as of September 30, 2024, compared to $18,153,609 as of December 31, 2023, marking an increase of about 14.2%[23] - Accounts receivable increased to $4,295,663 as of September 30, 2024, from $3,718,924 as of December 31, 2023, a rise of approximately 15.5%[23] - Selling, general, and administrative expenses totaled $26,755,892 for the three months ended September 30, 2024, slightly down from $26,862,973 in the same period of 2023[28] - The company reported a basic loss per share of $(0.05) for the three months ended September 30, 2024, compared to earnings of $0.09 for the same period in 2023[28] - Net cash provided by operating activities decreased to $5,284,936 for the nine months ended September 30, 2024, down from $11,294,757 in the prior year[29] - Net cash used in investing activities was $(527,294) for the nine months ended September 30, 2024, compared to $(4,883,148) in the previous year[29] - The company incurred stock compensation expense of $1,475,710 for the nine months ended September 30, 2024, compared to $1,209,296 in the prior year[30] - The company recognized deferred revenue of $(1,504,305) for the nine months ended September 30, 2024, compared to $(551,226) in the previous year[29] Strategic Initiatives - The company is committed to refranchising efforts and improving clinic economics to drive growth and profitability[3] - The company reported a significant increase in payroll liabilities to $2,621,327 for the nine months ended September 30, 2024, from $1,844,943 in the prior year[29] - The company reported a net loss on disposition or impairment of $5,602,641 for the nine months ended September 30, 2024, compared to $1,114,738 in the previous year[29]

Core Viewpoint - Gauzy Ltd. and Research Frontiers Inc. have announced a partnership, with Ferrari selecting Gauzy as a strategic supplier to incorporate Suspended Particle Device (SPD) technology into its vehicles for mass production [1][2] Company Overview - Gauzy Ltd. is a leader in light and vision control technology, headquartered in Tel Aviv, Israel, with a global presence in over 30 countries [8] - Research Frontiers Inc. develops and licenses SPD-Smart light-control film technology, which allows for precise control of shading in glass and plastic products [9] Partnership and Market Opportunities - The partnership with Ferrari marks the first mass production use of SPD technology in one of its prestigious models, indicating significant growth potential for smart glass applications in automotive, architectural, and aeronautical sectors [2][3] - The SPD smart glass market is projected to grow at a compound annual growth rate (CAGR) of 9.9% from 2024 to 2031, reaching a market value of $13.4 billion by the end of 2031 [3] Industry Applications - SPD technology is gaining traction in the automotive and aeronautics industries, providing benefits such as comfort, safety, aesthetics, energy efficiency, and thermal comfort [3][5] - Major automotive manufacturers, including McLaren, Mercedes, and Cadillac, have already integrated SPD smart glass into their vehicle designs, with expectations for wider adoption in mass-market cars [4] - In aeronautics, SPD technology is being incorporated into commercial airplanes, business jets, and helicopters to enhance passenger comfort and light control [5] Technology Features - SPD technology utilizes specially-engineered nanoparticles to control light dynamically, allowing up to 99% blocking of visible light, increasing head space in vehicles by at least 5 centimeters, and extending driving ranges in electric vehicles [6]

Company Overview - Helium Evolution Incorporated (HEVI) is a Canadian-based helium exploration company focused on developing assets in southern Saskatchewan, holding the largest helium land rights position in North America among publicly-traded companies with over five million acres under permit [6] Recent Exploration Activities - HEVI has provided an update on its exploration activities, including the results of a joint well (7-2 Well) where it holds a 20% working interest alongside North American Helium Inc. (NAH), which has reached total depth and the cased hole portion has been suspended for future exploration [2][4] - NAH plans to drill another joint well (10-1 Well) in the Mankota area, anticipated to spud in the coming days, as part of a development plan for up to nine wells in the area [3][4] Financial Position - The estimated total cost for HEVI's share in the 10-1 Well is approximately $0.4 million, supported by a strong working capital position of $4.7 million as of June 30, 2024, indicating the company's capability to fund its exploration initiatives [4] Strategic Commitment - HEVI's continued investment in the Mankota area underscores its commitment to expanding its footprint in the helium sector, aiming to become a leading supplier of sustainably-produced helium for the growing global market [4][6]

Apollo Biowellness, Inc. Announces Joint Venture/Partnership with Reveal Lasers LLC for Expanded Distribution and Collaboration of Evo Bio Products.October 31, 2024 9:30 AM EDT | Source: Apollo Biowellness, Inc.North Bergen, New Jersey--(Newsfile Corp. - October 31, 2024) - Apollo Biowellness, Inc. (OTC Pink: KOAN) is pleased to announce a joint venture and distribution partnership with Reveal Lasers LLC to expand the reach of Evolutionary Biologics, Inc.'s biologic products across the aesthet ...

Standard Uranium Provides Exploration Update Highlighting Successful Project Generation with New Joint Venture Ready Projects Available in 2025October 31, 2024 7:00 AM EDT | Source: Standard Uranium Ltd.Vancouver, British Columbia--(Newsfile Corp. - October 31, 2024) - Standard Uranium Ltd. (TSXV: STND) (OTCQB: STTDF) (FSE: 9SU0) ("Standard Uranium" or the "Company")is pleased to provide a summary of work programs on three of it's 100% owned uranium exploration projects currently under option ...

SCOTTSDALE, Ariz., Oct. 29, 2024 /PRNewswire/ -- The Joint Corp. (NASDAQ: JYNT), the nation's largest franchisor of chiropractic care through The Joint Chiropractic® network, announces its newest sponsorship agreement with Grand Canyon University Athletics. The brand has been named the Official Chiropractor of Grand Canyon University Athletics for a two-year term through 2026."We are honored to join Lope Country and support the student athletes of Grand Canyon University through our partnership," said Sanji ...

Companies announce expansion to technology alliance at Audit & Beyond Conference in Las VegasLAS VEGAS, Oct. 24, 2024 /PRNewswire/ -- AuditBoard, the leading cloud-based platform transforming audit, risk, and compliance management, and Protiviti, a global consulting firm with market leading expertise in internal audit, today announced new joint capabilities at Audit & Beyond, the premier event for audit, risk, and infosec leaders. The joint services include advanced analytics, collaboration, transformation, ...

VANCOUVER, BC, Oct. 24, 2024 /PRNewswire/ -- PlantX Life Inc. (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) ("PlantX" or the "Company"), a pioneer in building strong communities and operating innovative experiential online and in-store platforms that make it easier for individuals to lead happier, healthier lives, is thrilled to announce a joint venture with LIV3, founded by Christopher Mearns, to launch their SugarShield supplement. This collaboration is aimed at addressing the growing USD 5.24 billion glob ...